Navigation Links
Sentrx Exits 2008 with Strong Growth
Date:1/20/2009

Sentrx, a New Jersey drug safety specialty firm, announced today that the company grew the number of pharmacovigilance outsourcing contracts by more than 50% in 2008. Revenues for the year increased 25% over 2007. The domestic service provider added long-term contracts in clinical trial and post-marketing safety, managed safety system hosting, and risk evaluation and mitigation strategies. The company maintained its strong record of regulatory compliance during this period of growth.

Little Falls, NJ (PRWEB) January 20, 2009 - Sentrx, the leading provider of drug safety services, announced today that the company grew the number of pharmacovigilance outsourcing contracts by more than 50% in 2008. Revenues for the year increased 25% over 2007.

Sentrx pioneered the concept of drug safety outsourcing and safety system hosting for clinical trials and post-marketed products in 1999. Since that time, Sentrx has provided operational and consulting services to nearly eighty unique clients. More than fifty of those companies have outsourced adverse event processing, safety system management, or risk evaluation and mitigation strategies (REMS) to Sentrx.

Sentrx provides services from its headquarters in Little Falls, NJ. In addition to a staff of office-based health care professionals, the company utilizes its network of highly experienced drug safety investigators across the United States. This flexible workforce allows Sentrx to handle volume fluctuations and extended coverage hours for its clients, which benefit from the quality, reliability and convenience of a domestic service provider.

Highlights of new business in 2008 include:

¨ Managed safety system hosting for seven biopharmaceutical companies and a large generic manufacturer
¨ Post-marketing safety surveillance for two specialty pharmaceutical companies
¨ Clinical trial safety monitoring for four biopharmaceutical companies
¨ REMS with Elements to Assure Safe Use for a biopharmaceutical company
¨ Safety system consulting engagements at three large companies
¨ Data migration projects at two specialty pharmaceutical companies
¨ Risk management plans authored and approved for two New Drug Applications
¨ Contract renewal and expansion with several existing clients

Other accomplishments in 2008 include:

¨ Installation of Phase Forward's Empirica™ Trace 4.2 in the Sentrx Hosting Center
¨ Implementation of the first hosted client on Empirica Trace
¨ Positive results from seventeen qualification inspections and client audits
¨ Participation in eleven regulatory health authority inspections conducted at client sites with no major findings

"Growing revenue 25 % is a great accomplishment for Sentrx," said Joseph Albano, Chief Executive Officer of Sentrx, "but I am most proud of our consistent record of compliance. As our client base grows, so does the level of scrutiny our people, processes and technology undergo. The regulatory audit results combined with our financial results demonstrate that Sentrx is the drug safety services provider that companies can rely on."

About Sentrx
Sentrx is a leading provider of technology-enabled solutions and services for global drug safety. Its mission is to help pharmaceutical, biotechnology, medical device, and consumer health companies document the safety profile of their products during clinical development and post-approval, enabling them to minimize risks and maximize benefits. Through its multilingual Safety Response Center in Little Falls, NJ, Sentrx delivers a unique combination of highly skilled people, exclusive technology, and best practices in drug safety monitoring. To learn more about Sentrx, please call 1-888-399-8032, extension 261; visit the Sentrx website at www.sentrx.com; or
view the Sentrx movie at www.sentrx.com/impactmovie.

###

Read the full story at http://www.prweb.com/releases/2009/01/prweb1887034.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved

Related biology technology :

1. Matching Genetics, Technology and Management Practices Critical to Meeting Strong Demand for Agricultural Crops
2. China Biologic Products Reports Strong Third Quarter 2008 Results
3. ACORN CRO Continues Growth in Strong Third Quarter
4. Varian, Inc. Reports Strong Fourth Quarter 2008 Results
5. OmniComm Systems, Inc. Is Fueled by Another Strong Quarter Delivering Electronic Data Capture (EDC) Solutions & Services
6. Shires New Product Portfolio Delivers Strong Quarterly Performance
7. Cephalon Reports Another Strong Quarter
8. Innovation and Strong Therapeutic Potential Seen in Adult Stem Cells, According to Frost & Sullivan
9. Strong elasticity size effects in ZnO nanowires
10. Senetek Affirms Strong Financial Position
11. Dry adhesive based on carbon nanotubes gets stronger, with directional gripping ability
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... ... March 27, 2017 , ... A research team led ... grafts in JoVE’s Video Journal, the world’s first peer-reviewed scientific video journal. The ... treating coronary artery disease (CAD). Lam is an assistant professor at the Department ...
(Date:3/24/2017)... Md. , March 24, 2017  Infectex Ltd., ... (MBVF), today announced positive results of a Phase 2b-3 ... therapy regimen in patients with multidrug-resistant pulmonary tuberculosis (MDR-TB). ... scientists at Sequella, Inc. ( USA ) ... A total of 140 patients were enrolled in ...
(Date:3/24/2017)... LEXINGTON, Mass. , March 24, 2017 ... pipeline of immune checkpoint antibodies and cancer vaccines, today ... The 7 th  Annual William Blair and Maidstone ... Event Space Alexandria Center in New York, ... March 29 at 9:40 am: ...
(Date:3/23/2017)... 23, 2017  SeraCare Life Sciences, Inc., a ... vitro diagnostics manufacturers and clinical laboratories, is ... multiplexed Inherited Cancer reference material ... next-generation sequencing (NGS). The Seraseq™ Inherited Cancer DNA ... from industry experts to validate the ability ...
Breaking Biology Technology:
(Date:3/7/2017)... Brandwatch , the leading social intelligence company, today announces that it ... insights to support its reporting, help direct future campaigns, and share ... charity will be using Brandwatch Analytics social listening and analytics technology ... the topics and issues that are a priority for its supporters. ... "Until recently we,ve ...
(Date:3/2/2017)... 2, 2017 Summary This report provides ... its partnering interests and activities since 2010. ... Read the full report: ... since 2010 report provides an in-depth insight into the partnering ... On demand company reports are prepared upon purchase ...
(Date:3/2/2017)... March 2, 2017 Australian stem cell and ... CYP), has signed an agreement with the Monash Lung ... Biomedicine Discovery Institute and Department of Pharmacology at Monash ... further preclinical study to support the use of Cymerus™ ... Asthma is a chronic, long term ...
Breaking Biology News(10 mins):